Articles with public access mandates - ParrenLearn more
Not available anywhere: 3
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
J Boshuizen, LA Koopman, O Krijgsman, A Shahrabi, EG van den Heuvel, ...
Nature Medicine 24 (2), 203-212, 2018
Mandates: European Commission, Dutch Cancer Society
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity
C Kellner, T Maurer, D Hallack, R Repp, JGJ van de Winkel, PWHI Parren, ...
The Journal of Immunology 189 (10), 5037-5046, 2012
Mandates: German Research Foundation
Monoclonal antibodies against epidermal growth factor receptor acquire an ability to kill tumor cells through complement activation by mutations that selectively facilitate the …
A Tammen, S Derer, R Schwanbeck, T Rösner, A Kretschmer, ...
The Journal of Immunology 198 (4), 1585-1594, 2017
Mandates: German Research Foundation
Available somewhere: 37
Fc receptor but not complement binding is important in antibody protection against HIV
AJ Hessell, L Hangartner, M Hunter, CEG Havenith, FJ Beurskens, ...
Nature 449 (7158), 101-104, 2007
Mandates: Swiss National Science Foundation
Complement is activated by IgG hexamers assembled at the cell surface
CA Diebolder, FJ Beurskens, RN De Jong, RI Koning, K Strumane, ...
Science 343 (6176), 1260-1263, 2014
Mandates: US National Institutes of Health, European Commission
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
AJ Hessell, P Poignard, M Hunter, L Hangartner, DM Tehrani, WK Bleeker, ...
Nature medicine 15 (8), 951-954, 2009
Mandates: Swiss National Science Foundation, US National Institutes of Health
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
M Peipp, JJ Lammerts van Bueren, T Schneider-Merck, WWK Bleeker, ...
Blood, The Journal of the American Society of Hematology 112 (6), 2390-2399, 2008
Mandates: German Research Foundation
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid …
T Schneider-Merck, JJ Lammerts van Bueren, S Berger, K Rossen, ...
The journal of immunology 184 (1), 512-520, 2010
Mandates: German Research Foundation
A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface
RN de Jong, FJ Beurskens, S Verploegen, K Strumane, MD van Kampen, ...
PLoS biology 14 (1), e1002344, 2016
Mandates: Netherlands Organisation for Scientific Research
Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement
D Ugurlar, SC Howes, BJ de Kreuk, RI Koning, RN de Jong, FJ Beurskens, ...
Science 359 (6377), 794-797, 2018
Mandates: Netherlands Organisation for Scientific Research, European Commission
Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen
G Wang, RN de Jong, ETJ van den Bremer, FJ Beurskens, AF Labrijn, ...
Molecular Cell 63 (1), 135-145, 2016
Mandates: Netherlands Organisation for Scientific Research
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients
FJ Beurskens, MA Lindorfer, M Farooqui, PV Beum, P Engelberts, ...
The Journal of Immunology 188 (7), 3532-3541, 2012
Mandates: US National Institutes of Health
A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcγRIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection …
B Moldt, M Shibata-Koyama, EG Rakasz, N Schultz, Y Kanda, DC Dunlop, ...
Journal of virology 86 (11), 6189-6196, 2012
Mandates: US National Institutes of Health
ADCT-301, a pyrrolobenzodiazepine (PBD) dimer–containing antibody–drug conjugate (ADC) targeting CD25-expressing hematological malignancies
MJ Flynn, F Zammarchi, PC Tyrer, AU Akarca, N Janghra, CE Britten, ...
Molecular cancer therapeutics 15 (11), 2709-2721, 2016
Mandates: Cancer Research UK
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
J Neijssen, RMF Cardoso, KM Chevalier, L Wiegman, T Valerius, ...
Journal of Biological Chemistry 296, 2021
Mandates: US Department of Energy
Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces
J Strasser, RN de Jong, FJ Beurskens, G Wang, AJR Heck, J Schuurman, ...
Nano letters 19 (7), 4787-4796, 2019
Mandates: Netherlands Organisation for Scientific Research
The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia–microenvironment interactions in chronic lymphocytic leukemia
A Matas-Céspedes, A Vidal-Crespo, V Rodriguez, N Villamor, J Delgado, ...
Clinical Cancer Research 23 (6), 1493-1505, 2017
Mandates: US National Institutes of Health, Government of Spain
Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques
B Moldt, KM Le, DG Carnathan, JB Whitney, N Schultz, MG Lewis, ...
Aids 30 (10), 1543-1551, 2016
Mandates: Bill & Melinda Gates Foundation, US National Institutes of Health
C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases
SA Zwarthoff, K Widmer, A Kuipers, J Strasser, M Ruyken, PC Aerts, ...
Proceedings of the National Academy of Sciences 118 (26), e2102787118, 2021
Mandates: Swiss National Science Foundation, Austrian Science Fund, European Commission
The INNs and outs of antibody nonproprietary names
TD Jones, PJ Carter, A Plückthun, M Vásquez, RGE Holgate, I Hötzel, ...
MAbs 8 (1), 1-9, 2016
Mandates: US Department of Energy
Publication and funding information is determined automatically by a computer program